Cargando…

Use of Plerixafor to Mobilize a Healthy Donor Infected with Influenza A

Detalles Bibliográficos
Autores principales:	Yeral, Mahmut, Aytan, Pelin, Boğa, Can
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Galenos Publishing 2018
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5972339/ https://www.ncbi.nlm.nih.gov/pubmed/29391335 http://dx.doi.org/10.4274/tjh.2017.0304

Ejemplares similares

Is the Game Over or Starting Again? The Role of the Transplant Team in Genetic Counseling for Adult Sickle Cell Disease Recipients
por: Aytan, Pelin, et al.
Publicado: (2017)

Demodicidosis Accompanying Acute Cutaneous Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation
por: Aytan, Pelin, et al.
Publicado: (2018)

Is Sickle Cell Trait Really Innocent?
por: Yeral, Mahmut, et al.
Publicado: (2021)

Implementation of an ISBT 128-Compatible Medical Record System to Facilitate Traceability of Stem Cell Products
por: Boğa, Can, et al.
Publicado: (2017)

An Unusual Giant Leg Ulcer as a Rare Presentation of Sweet’s Syndrome in a Patient with Hairy Cell Leukemia Successfully Managed by Splenectomy
por: Özdoğu, Hakan, et al.
Publicado: (2017)

Percutaneous Vertebroplasty for Osteoporotic Vertebral Fracture in a Patient with Sickle Cell Disease
por: Yeral, Mahmut, et al.
Publicado: (2012)

Plerixafor as a preemptive or salvage therapy for healthy donors with poor mobilization of hematopoietic stem cells
por: Kuang, Pu, et al.
Publicado: (2022)

Addition of plerixafor in poorly mobilized allogeneic stem cell donors
por: Zhuang, Lefan, et al.
Publicado: (2022)

Use of Mesenchymal Cells to Modulate Immune Suppression and Immune Reconstruction in a Patient with Aplastic Anemia Complicated by Invasive Sino-Orbital Aspergillosis
por: Özdoğu, Hakan, et al.
Publicado: (2014)

Therapy-related Myelodysplastic Syndrome after Autologous Stem Cell Transplantation Using Plerixafor for Mobilized Stem Cells in a Patient with Multiple Myeloma
por: Tanaka, Hiroaki, et al.
Publicado: (2018)

Organ damage mitigation with the Baskent Sickle Cell Medical Care Development Program (BASCARE)
por: Ozdogu, Hakan, et al.
Publicado: (2018)

Successful mobilization using a combination of plerixafor and G-CSF in pediatric patients who failed previous chemomobilization with G-CSF alone and possible complications of the treatment
por: Hong, Kyung Taek, et al.
Publicado: (2012)

Hematopoietic Stem Cell Mobilization With Plerixafor Is Safe and Effective in Poorly Mobilizing Acute Myeloid Leukemia Patients
por: Shumilov, Evgenyi, et al.
Publicado: (2019)

Safe and efficient peripheral blood stem cell collection in patients with sickle cell disease using plerixafor
por: Uchida, Naoya, et al.
Publicado: (2020)

Effect of high-dose plerixafor on CD34(+) cell mobilization in healthy stem cell donors: results of a randomized crossover trial
por: Pantin, Jeremy, et al.
Publicado: (2017)

Plerixafor
por: Slater, Susan
Publicado: (2012)

Plerixafor for autologous CD34(+) cell mobilization
por: Salman, Huda, et al.
Publicado: (2011)

Effectiveness of Visual Methods in Information Procedures for Stem Cell Recipients and Donors
por: Sarıtürk, Çağla, et al.
Publicado: (2017)

An Approach to Pediatric or Mentally Deficient Donors from a Bioethical Perspective: Considerations and Recommendations on Behalf of the Donor Research Team of the Turkish Society of Hematology (DART)
por: Keleş, Şükrü, et al.
Publicado: (2022)

Plerixafor use for peripheral blood stem cell mobilization in Korea
por: Kim, Seok Jin, et al.
Publicado: (2013)

A phase 1/2 study of chemosensitization with plerixafor plus G-CSF in relapsed or refractory acute myeloid leukemia
por: Uy, G L, et al.
Publicado: (2017)

Influenza A Infection and Stem Cell Mobilization
por: Yasri, Sora, et al.
Publicado: (2018)

Efficacy of Afternoon Plerixafor Administration for Stem Cell Mobilization
por: El Rahi, Cynthia, et al.
Publicado: (2018)

Mobilization of healthy donors with plerixafor affects the cellular composition of T-cell receptor (TCR)-αβ/CD19-depleted haploidentical stem cell grafts
por: Rutella, Sergio, et al.
Publicado: (2014)

Salvage treatment with plerixafor in poor mobilizing allogeneic stem cell donors: results of a prospective phase II-trial
por: Hölig, Kristina, et al.
Publicado: (2020)

Tunnelled Central Venous Catheter-Related Problems in the Early Phase of Haematopoietic Stem Cell Transplantation and Effects on Transplant Outcome
por: Yeral, Mahmut, et al.
Publicado: (2015)

Correction to: Salvage treatment with plerixafor in poor mobilizing allogeneic stem cell donors: results of a prospective phase II-trial
por: Hölig, Kristina, et al.
Publicado: (2021)

A Rare Complication Developing After Hematopoietic Stem Cell Transplantation: Wernicke’s Encephalopathy
por: Solmaz, Soner, et al.
Publicado: (2015)

Plerixafor in the Treatment of Stem Cell Mobilization Failure; First Experience in Iran
por: Mehdizadeh, Mahshid, et al.
Publicado: (2013)

Diabetes Limits Stem Cell Mobilization Following G-CSF but Not Plerixafor
por: Fadini, Gian Paolo, et al.
Publicado: (2015)

Plerixafor stem cell mobilization in Japanese children: A post‐marketing study
por: Goto, Hiroaki, et al.
Publicado: (2022)

Human Gyrovirus in Healthy Blood Donors, France
por: Biagini, Philippe, et al.
Publicado: (2013)

Use of Plerixafor for Stem Cell Mobilization in the Setting of Autologous and Allogeneic Stem Cell Transplantations: An Update
por: Bilgin, Yavuz M
Publicado: (2021)

Human Herpesvirus 8 in Healthy Blood Donors, Argentina
por: Pérez, Celeste L., et al.
Publicado: (2010)

What the Largest Earthquake in 100 Years Has Taught Us: Real-Life Data from a JACIE-Accredited Bone Marrow Transplant Center
por: Kozanoğlu, İlknur, et al.
Publicado: (2023)

The feasibility and efficacy of subcutaneous plerixafor for mobilization of peripheral blood stem cells in allogeneic HLA–identical sibling donors: results of the HOVON‐107 study
por: de Greef, Georgine E., et al.
Publicado: (2018)

Mobilizing hematopoietic progenitor cells in donors with sickle cell trait is safe
por: De Santis, Gil Cunha, et al.
Publicado: (2019)

P1343: TRANSPLANT OUTCOMES OF LYMPHOMA PATIENTS UNDERGOING STEM CELL MOBILIZATION WITH PLERIXAFOR
por: Gunes, A. K., et al.
Publicado: (2022)

Plerixafor as a salvage mobilization strategy for haploidentical peripheral blood allogeneic stem cell transplantation
por: Nadeau, Michelle, et al.
Publicado: (2015)

Use of Plerixafor for Stem Cell Mobilization in the Setting of Autologous and Allogeneic Stem Cell Transplantations: An Update [Corrigendum]
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5o9omsf2sn9kfs254r29579kqj